| Catalog No. | HY105016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | FLT2, HBGFR, BFGFR, FGFR-1, CEK, Fibroblast growth factor receptor 1, FGFR1, bFGF-R-1, Fms-like tyrosine kinase 2, FGFBR, FLT-2, CD331, Basic fibroblast growth factor receptor 1, FLG, Proto-oncogene c-Fgr, N-sam, Klotho beta-like protein, KLB, Beta-klotho, BetaKlotho, BKL |
|---|
| Concentration | 3.06mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P11362 & Q86Z14 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -811°C. |
|---|
| Alternate Names | Bispecific,BFKB8488A,CAS:2517935-02-1 |
|---|
| Background | Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
